Pacific Biosciences Of California (PACB) Total Non-Current Liabilities (2010 - 2026)

Pacific Biosciences Of California's Total Non-Current Liabilities history runs 16 years deep, the most recent figure standing at $772.0 million for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities changed 0.37% year-over-year to $772.0 million in Q1 2026; TTM through Mar 2026 was $772.0 million, a 0.37% change from a year earlier, with the FY2025 full-year figure at $778.7 million, up 5.93% from the prior year.
• Total Non-Current Liabilities slipped to $772.0 million in Q1 2026 per PACB's latest filing, from $778.7 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $1.2 billion in Q2 2023 and bottomed at $735.2 million in Q4 2024.
• The 5-year median for Total Non-Current Liabilities is $1.0 billion (2023), against an average of $966.0 million.
• Across the five-year window, Total Non-Current Liabilities surged 620.77% in 2022 and retreated 29.58% in 2024, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $1.2 billion in 2022, then decreased by 13.21% to $1.0 billion in 2023, then slipped by 29.58% to $735.2 million in 2024, then rose by 5.93% to $778.7 million in 2025, then fell by 0.86% to $772.0 million in 2026.
• Per Business Quant, the three latest PACB Total Non-Current Liabilities figures stand at $772.0 million (Q1 2026), $778.7 million (Q4 2025), and $767.1 million (Q3 2025).